Department of Cardiology, Johns Hopkins University, School of Medicine, Baltimore, Maryland; U.S. Food and Drug Administration, Center for Devices and Radiological Health, Silver Spring, Maryland; Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City, School of Medicine, Kansas City, Missouri.
U.S. Food and Drug Administration, Center for Devices and Radiological Health, Silver Spring, Maryland.
JACC Clin Electrophysiol. 2018 Sep;4(9):1189-1199. doi: 10.1016/j.jacep.2018.06.020. Epub 2018 Aug 29.
This study examined the trend in growth of catheter ablation for ventricular tachycardia (VT) performed in the United States with analysis of rates and predictors of major adverse events.
Sustained VT is a significant cause of sudden death, heart failure (HF), and recurrent shocks in implantable cardioverter-defibrillator (ICD) recipients. Catheter ablation for VT reduces arrhythmia recurrence. Limited data are available regarding the use, safety, and long-term outcomes after VT ablation.
Using the U.S. Medicare database linked to the Social Security Death Index, we examined the annual use of VT ablation in 21,073 patients over 12 years, with 30-day risk of mortality, nonfatal major adverse events (MAEs), 1-year risk of mortality, re-hospitalization, repeat ablation, and factors associated with adverse outcomes.
Among 21,073 patients (age 70 ± 9 years; 77% men; 90% white), there were 1,581 (7.5%) non-fatal MAEs within 30 days. There were 963 (4.6%) vascular complications, 485 (2.3%) pericardial complications, and 201 (1%) strokes and/or transient ischemic attacks. Mechanical circulatory support use was infrequent (2.3%). The 30-day and 1-year mortality rates were 4.2% and 15.0%, respectively. The 1-year incidence of repeat ablation was 10.2 per 100 person-years and re-hospitalization for HF or VT was 15.4 per 100 person-years and 18 per 100 person-years, respectively. Patients with an ICD had increased 30-day (4.9% vs. 0.86%) and 1-year mortality (17.5% vs. 2.54% [22.9 per 100 person-years vs. 3.1 per 100 person-years]; hazard ratio [HR]: 2.93; 95% confidence interval [CI]: 2.21 to 3.88). Rates of hospitalization for HF (18 per 100 person-years vs. 1.8 per 100 person-years; HR: 4.00; 95% CI: 2.78 to 5.78) or VT recurrence (22.7 per 100 person-years vs. 2.1 per 100 person-years; HR: 5.70; 95% CI: 4.09 to 7.96) were also higher at 1 year. Between 2000 and 2012, annual VT ablation volumes increased >4-fold.
Catheter ablation for VT is frequently performed. Short-term MAEs and 1-year mortality is significant and is highest in patients with an ICD. These findings may provide greater insight of outcomes in an unselected real-world population undergoing VT ablation.
本研究通过分析主要不良事件的发生率和预测因素,考察了美国经导管消融治疗室性心动过速(VT)的增长趋势。
持续性 VT 是植入式心脏复律除颤器(ICD)受者发生心源性猝死、心力衰竭(HF)和反复电击的重要原因。VT 消融术可减少心律失常的复发。关于 VT 消融术的使用、安全性和长期结果,目前仅有有限的数据。
我们使用美国医疗保险数据库与社会安全死亡索引相链接,对 12 年间 21073 例患者的 VT 消融术年使用情况进行了检查,包括 30 天的死亡率、非致死性主要不良事件(MAE)、1 年的死亡率、再住院率、重复消融术以及与不良结局相关的因素。
在 21073 例患者(年龄 70 ± 9 岁;77%为男性;90%为白人)中,30 天内有 1581 例(7.5%)发生非致死性 MAE。有 963 例(4.6%)发生血管并发症,485 例(2.3%)发生心包并发症,201 例(1%)发生卒中和/或短暂性脑缺血发作。机械循环支持的使用较为少见(2.3%)。30 天和 1 年死亡率分别为 4.2%和 15.0%。1 年重复消融术的发生率为每 100 人年 10.2 次,HF 或 VT 再住院率分别为每 100 人年 15.4 次和 18 次。植入 ICD 的患者 30 天(4.9%比 0.86%)和 1 年死亡率(17.5%比 2.54%[22.9 例/100 人年比 3.1 例/100 人年];危险比[HR]:2.93;95%置信区间[CI]:2.21 至 3.88)均增加。HF(18 例/100 人年比 1.8 例/100 人年;HR:4.00;95%CI:2.78 至 5.78)或 VT 复发(22.7 例/100 人年比 2.1 例/100 人年;HR:5.70;95%CI:4.09 至 7.96)的 1 年住院率也更高。2000 年至 2012 年间,VT 消融术的年手术量增加了 4 倍以上。
VT 的导管消融术经常进行。短期 MAE 和 1 年死亡率很高,在植入 ICD 的患者中更高。这些发现可能为接受 VT 消融术的未选择的真实世界人群的结局提供更深入的了解。